Dabur Pharma Of India To Sell Majority Interest To Fresenius
This article was originally published in PharmAsia News
Executive Summary
India's Dabur Pharma agreed to sell a nearly three-quarters interest in the company to Fresenius Kabi of Singapore. Fresenius Kabi is a subsidiary of Fresenius SE, a global company based in Germany. Darbur's founder and director, Anand Burman, said his company agreed to sell Fesenius a 73.27 percent interest because it needed to integrate with a global company capable of expanding the firm more quickly. He noted Dabur has been getting its drugs approved around the world and it would not have made sense to attempt to market them by itself. (Click here for more